
Choksi Laboratories Ltd is Rated Hold by MarketsMOJO
2026-11-19 10:10:43Choksi Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 November 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Choksi Laboratories Ltd is Rated Hold by MarketsMOJO
2026-10-30 10:10:48Choksi Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Choksi Laboratories Ltd is Rated Hold
2026-10-19 10:11:04Choksi Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 October 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Broad-Based Technical Strength Lifts Choksi Laboratories Ltd to 52-Week High of Rs 226.65
2026-10-15 09:45:01With a decisive break above Rs 226.65 on 15 Jun 2026, Choksi Laboratories Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This surge comes after a sustained five-day rally that has delivered a 17.04% gain, outpacing its healthcare services sector peers and reflecting a strong technical alignment across multiple timeframes.
Read More
Broad-Based Technical Strength Lifts Choksi Laboratories Ltd to 52-Week High of Rs 217.75
2026-10-14 09:44:25With a decisive break above Rs 217.75 on 14 Oct 2026, Choksi Laboratories Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This surge comes after a sustained four-day rally delivering nearly 15% returns, outpacing its healthcare services sector peers and the broader market.
Read MoreChoksi Laboratories Gains 4.11%: Valuation and Technicals Drive Weekly Momentum
2026-10-10 17:02:33Key Events This Week 5 Oct: Valuation shifts to very attractive amid mixed market performance 7 Oct: Upgrade to Hold on improved technicals and valuation 9 Oct: Week closes at ₹192.35 (+4.11%) outperforming Sensex Week OpenRs.184.75 Week CloseRs.192.35+4.11% <div cla...
Read More
Choksi Laboratories Ltd Upgraded to Hold on Improved Technicals and Valuation
2026-10-08 08:04:52Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Sell to Hold as of 7 October 2026. This change reflects improvements across technical indicators and valuation metrics, despite flat recent financial performance. The company’s stock has demonstrated strong market-beating returns over multiple time horizons, prompting a reassessment of its investment appeal.
Read More
Choksi Laboratories Ltd Valuation Shifts to Very Attractive Amid Mixed Market Performance
2026-10-05 08:01:34Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen its valuation parameters shift notably, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving from attractive to very attractive territory. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s valuation metrics suggest a compelling price attractiveness compared to its historical averages and peer group, warranting a closer examination by investors.
Read More
Choksi Laboratories Downgraded to Sell Amid Mixed Fundamentals and Technical Signals
2026-10-02 08:08:00Choksi Laboratories Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Hold to Sell as of 1 Oct 2026. This change reflects a complex interplay of factors including a shift in technical indicators, an improved valuation grade, flat financial trends, and concerns over long-term quality metrics. Despite a very attractive valuation and strong relative returns over the medium term, the company’s weak fundamentals and mixed technical signals have prompted a cautious stance from analysts.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSESubmission of newspaper publication of the financial result for the period ended 30.09.2026
Board Meeting Outcome for Meeting Of Board Of Directors Held On 14.11.2026
14-Nov-2026 | Source : BSE1. Considered and approved the Unaudited Financial Results for the Quarter and Half Year ended on 30th September 2026 along with the Limited review report;
Submission Of Financial Result For The Quarter And Half Year Ended 30.09.2026
14-Nov-2026 | Source : BSEConsidered and approved the Unaudited Financial Results for the quarter and half year ended on 30th September2026 along with the Limited Review Report
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available